This cancer-targeted design of Se NPs provides a new strategy for synergistic treating of cancer with higher efficacy and decreased side effects, suggesting GE11-Ori-Se NPs as a candidate for further evaluation as a chemotherapeutic agent for human cancers, especially for EGFR over-expressed esophageal cancers. The gene discussed is EGFR; the disease is esophageal cancer.